Complement and cytokine based therapeutic strategies in myasthenia gravis

Vincent, 2002, Myasthenia gravis, Adv Neurol, 88, 159 Conti-Fine, 2006, Myasthenia gravis: past, present, and future, J Clin Invest, 116, 2843, 10.1172/JCI29894 Christadoss, 2000, Animal models of myasthenia gravis, Clin Immunol, 94, 75, 10.1006/clim.1999.4807 Tüzün, 2003, Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis, J Immunol, 171, 3847, 10.4049/jimmunol.171.7.3847 Conti-Fine, 2008, CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis, Ann N Y Acad Sci, 1132, 193, 10.1196/annals.1405.042 Childs, 1987, Complement-mediated muscle damage produced by myasthenic sera, Ann N Y Acad Sci, 505, 180, 10.1111/j.1749-6632.1987.tb51291.x Engel, 1981, The immunopathology of acquired myasthenia gravis, Ann N Y Acad Sci, 377, 158, 10.1111/j.1749-6632.1981.tb33730.x Drachman, 1980, Mechanisms of acetylcholine receptor loss in myasthenia gravis, J Neurol Neurosurg Psychiatry, 43, 601, 10.1136/jnnp.43.7.601 Tarr, 2005, Immune function of C1q and its modulators CD91 and CD93, Crit Rev Immunol, 25, 305, 10.1615/CritRevImmunol.v25.i4.40 Zachrau, 2004, Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice, Int Immunol, 16, 1685, 10.1093/intimm/dxh159 Nastuk, 1960, Changes in serum complement activity in patients with myasthenia gravis, Proc Soc Exp Biol Med, 105, 177, 10.3181/00379727-105-26050 Sahashi, 1980, Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis, J Neuropathol Exp Neurol, 39, 160, 10.1097/00005072-198003000-00005 Engel, 1977, Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations, Mayo Clin Proc, 52, 267 Romi, 2005, The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo, J Neuroimmunol, 158, 191, 10.1016/j.jneuroim.2004.08.002 Liu, 2009, Correlation of C3 level with severity of generalized myasthenia gravis, Muscle Nerve, 40, 801, 10.1002/mus.21398 Tüzün, 2006, Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis, Neuromuscul Disord, 16, 137, 10.1016/j.nmd.2005.11.005 Tüzün, 2004, Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice, J Immunol, 172, 5743, 10.4049/jimmunol.172.9.5743 Leite, 2008, IgG1 antibodies to acetylcholine receptors in ’seronegative’ myasthenia gravis, Brain, 131, 1940, 10.1093/brain/awn092 Yang, 2007, A new mouse model of autoimmune ocular myasthenia gravis, Invest Ophthalmol Vis Sci, 48, 5101, 10.1167/iovs.07-0271 Lennon, 1978, Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis, J Exp Med, 147, 973, 10.1084/jem.147.4.973 Piddlesden, 1996, Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis, J Neuroimmunol, 71, 173, 10.1016/S0165-5728(96)00144-0 Biesecker, 1989, Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6, J Immunol, 142, 2654, 10.4049/jimmunol.142.8.2654 Zhou, 2007, Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis, J Immunol, 179, 8562, 10.4049/jimmunol.179.12.8562 Soltys, 2009, Novel complement inhibitor limits severity of experimentally myasthenia gravis, Ann Neurol, 65, 67, 10.1002/ana.21536 Tüzün, 2007, Pros and cons of treating murine myasthenia gravis with anti-C1q antibody, J Neuroimmunol, 182, 167, 10.1016/j.jneuroim.2006.10.014 Pták, 2005, Immunoadsorption therapy and complement activation, Transfus Apheresis Sci, 32, 263, 10.1016/j.transci.2004.07.014 Christadoss, 1988, C5 gene influences the development of murine myasthenia gravis, J Immunol, 140, 2589, 10.4049/jimmunol.140.8.2589 Chamberlain-Banoub, 2006, Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats, Clin Exp Immunol, 146, 278, 10.1111/j.1365-2249.2006.03198.x Liang, 2011, The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss, J Immunol, 186, 869, 10.4049/jimmunol.1003252 Qi, 2008, C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis, J Neuroimmunol, 196, 101, 10.1016/j.jneuroim.2008.03.007 Rødgaard, 1987, Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3, Clin Exp Immunol, 67, 82 Tüzün, 2006, Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis, J Neuroimmunol, 174, 157, 10.1016/j.jneuroim.2006.01.015 Li, 2009, Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis, J Neuroimmunol, 208, 40, 10.1016/j.jneuroim.2008.12.013 Nataf, 2000, Attenuation of experimental autoimmune demyelination in complement-deficient mice, J Immunol, 165, 5867, 10.4049/jimmunol.165.10.5867 Kaminski, 2004, Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis, Exp Neurol, 189, 333, 10.1016/j.expneurol.2004.06.005 Kaminski, 2006, Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia, Exp Neurol, 202, 287, 10.1016/j.expneurol.2006.06.003 Morgan, 2006, The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice, Clin Exp Immunol, 146, 294, 10.1111/j.1365-2249.2006.03205.x Tüzün, 2006, Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis, J Neuroimmunol, 181, 29, 10.1016/j.jneuroim.2006.07.016 Yapici, 2007, High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia gravis, Int J Neurosci, 117, 1505, 10.1080/00207450601125840 Soltys, 2008, Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?, Ann N Y Acad Sci, 1132, 220, 10.1196/annals.1405.037 Heckmann, 2010, A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis, Genes Immun, 11, 1, 10.1038/gene.2009.61 Leite, 2007, Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status, Am J Pathol, 171, 893, 10.2353/ajpath.2007.070240 Poussin, 2002, Role of IL-5 during primary and secondary immune response to acetylcholine receptor, J Neuroimmunol, 125, 51, 10.1016/S0165-5728(02)00030-9 Deng, 2002, Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production, J Immunol, 169, 1077, 10.4049/jimmunol.169.2.1077 Deng, 1996, IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis, J Immunol, 157, 5675, 10.4049/jimmunol.157.12.5675 Huang, 2001, Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis, Eur J Immunol, 31, 225, 10.1002/1521-4141(200101)31:1<225::AID-IMMU225>3.0.CO;2-0 Yang, 2005, IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1, J Immunol, 175, 2018, 10.4049/jimmunol.175.3.2018 Balasa, 1998, The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis, J Immunol, 161, 2856, 10.4049/jimmunol.161.6.2856 Ostlie, 2003, Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice, J Immunol, 170, 604, 10.4049/jimmunol.170.1.604 Aricha, 2011, Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis, J Autoimmun, 36, 135, 10.1016/j.jaut.2010.12.001 Poussin, 2000, Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR, J Neuroimmunol, 111, 152, 10.1016/S0165-5728(00)00385-4 Wang, 2007, C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells, J Immunol, 178, 7072, 10.4049/jimmunol.178.11.7072 Karachunski, 2000, Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice, J Immunol, 164, 5236, 10.4049/jimmunol.164.10.5236 Im, 2001, Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18, FASEB J, 15, 2140, 10.1096/fj.01-0072com Christadoss, 2002, Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein, J Neuroimmunol, 122, 186, 10.1016/S0165-5728(01)00473-8 Goluszko, 2001, Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis, J Neuroimmunol, 113, 109, 10.1016/S0165-5728(00)00420-3 Goluszko, 2002, Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis, J Neuroimmunol, 122, 85, 10.1016/S0165-5728(01)00474-X Wang, 2000, Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis, Int Immunol, 12, 1381, 10.1093/intimm/12.10.1381 Tuzun, 2010, Targeting classical complement pathway and IL-6, 327 Sitaraman, 2000, Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice, J Neuroimmunol, 107, 73, 10.1016/S0165-5728(00)00259-9 Wang, 2004, The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells, J Immunol, 172, 97, 10.4049/jimmunol.172.1.97 Zhang, 1999, Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis, J Immunol, 162, 3775, 10.4049/jimmunol.162.7.3775 Balasa, 1997, Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice, J Exp Med, 186, 385, 10.1084/jem.186.3.385 Mu, 2009, Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis, Immunology, 128, 10.1111/j.1365-2567.2009.03089.x Yang, 2010, Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile, Inflamm Res, 59, 197, 10.1007/s00011-009-0087-6 Kong, 2009, BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO, Eur J Immunol, 39, 800, 10.1002/eji.200838729 Masuda, 2010, Clinical implication of peripheral CD4+CD25+regulatory T cells and Th17 cells in myasthenia gravis patients, J Neuroimmunol, 225, 123, 10.1016/j.jneuroim.2010.03.016 Rowin, 2004, Etanercept treatment in corticosteroid-dependent myasthenia gravis, Neurology, 63, 2390, 10.1212/01.WNL.0000147242.92691.71 Adikari, 2004, Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis, Clin Exp Immunol, 138, 230, 10.1111/j.1365-2249.2004.02585.x Duan, 2004, Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells, Neurobiol Dis, 16, 461, 10.1016/j.nbd.2004.03.017 Meriggioli, 2008, Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis, Ann N Y Acad Sci, 1132, 276, 10.1196/annals.1405.023 Xiao, 2006, The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis, Cell Immunol, 241, 95, 10.1016/j.cellimm.2006.08.005 Stegall, 2000, Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis, Clin Immunol, 94, 133, 10.1006/clim.1999.4822 Tüzün, 2006, Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells, Cytokine, 35, 100, 10.1016/j.cyto.2006.05.009 Parker, 2009, Eculizumab for paroxysmal nocturnal haemoglobinuria, Lancet, 373, 759, 10.1016/S0140-6736(09)60001-5 Spitzer, 2004, ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement, Mol Immunol, 40, 911, 10.1016/j.molimm.2003.10.017 Mitchell, 1996, IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA, J Immunol, 156, 4429, 10.4049/jimmunol.156.11.4429 Youinou, 2010, Moutsopoulos: a lifetime in autoimunity, J Autoimmun, 35, 171, 10.1016/j.jaut.2010.06.003 Juran, 2010, Update on the genetics and genomics of PBC, J Autoimmun, 35, 181, 10.1016/j.jaut.2010.06.005 Mackay, 2010, The odd couple: a fresh look at autoimmunity and immunodeficiency, J Autoimmun, 35, 199, 10.1016/j.jaut.2010.06.008 Mavragani, 2010, Activation of the type I interferon pathway in primary Sjogren’s syndrome, J Autoimmun, 35, 225, 10.1016/j.jaut.2010.06.012 Scheinecker, 2010, Pathogenetic aspects of systemic lupus erythematosus with an emphasis on reglatory T cells, J Autoimmun, 35, 269, 10.1016/j.jaut.2010.06.018 Wiik, 2010, Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells, J Autoimmun, 35, 276, 10.1016/j.jaut.2010.06.019 Youinou, 2010, The international symposium on Sjogren’s syndrome in Brest: the "top of the tops" at the "tip of the tips", Autoimmun Rev, 9, 589, 10.1016/j.autrev.2010.05.014 Saraux, 2010, The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren’s syndrome, Autoimmun Rev, 9, 589, 10.1016/j.autrev.2010.05.007 Meroni, 2010, Systemic lupus erythematosus and the SLE galaxy, Autoimmun Rev, 10, 1, 10.1016/j.autrev.2010.09.006 Katz, 2010, Drug-induced lupus: an update, Autoimmun Rev, 10, 46, 10.1016/j.autrev.2010.07.005 Andreoli, 2010, Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges, Autoimmun Rev, 10, 51, 10.1016/j.autrev.2010.08.004 Youinou, 2010, Geo-epidemiology and autoimmunity, J Autoimmun, 34, J163, 10.1016/j.jaut.2009.12.005 Hoffmann, 2010, Nucleic acid-association autoantigens: pathogenic involvement and therapeutic potential, J Autoimmun, 34, J178, 10.1016/j.jaut.2009.11.013 Powell, 2010, Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract, J Autoimmun, 34, J226, 10.1016/j.jaut.2009.11.006 Maverakis, 2010, Light, including ultraviolet, J Autoimmun, 34, J247, 10.1016/j.jaut.2009.11.011 Schilder, 2010, Wegener’s granulomatosis vasculitis and granuloma, Autoimmun Rev, 9, 477, 10.1016/j.autrev.2010.02.006 Tahir, 2010, Current remedies for vitiligo, Autoimmun Rev, 9, 516, 10.1016/j.autrev.2010.02.013 Ansari, 2009, Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose, J Autoimmun, 33, 165, 10.1016/j.jaut.2009.07.007 Mackay, 2009, Clustering and commonalities among autoimmune diseases, J Autoimmun, 33, 170, 10.1016/j.jaut.2009.09.006 Chiorini, 2009, Sjogren syndrome: advances in the pathogenesis from animal models, J Autoimun, 33, 190, 10.1016/j.jaut.2009.09.009 Kong, 2009, Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function, J Autoimmun, 33, 239, 10.1016/j.jaut.2009.09.004 Leuschner, 2009, Autoimmune myocarditis: past, present and future, J Autoimmun, 33, 282, 10.1016/j.jaut.2009.07.009